In Q2 2026, FMC Corp implemented the main actions of its previously announced Project Foundation cost optimization plan, including exiting certain high-cost manufacturing sites and transitioning production to lower-cost facilities. Concurrently, the company advanced regulatory approvals for new crop protection active ingredients, notably filing for EPA review of rimisoxafen. FMC also progressed with divesting its India commercial business as part of portfolio reshaping. On the financial front, FMC issued $1.2 billion of senior secured notes to refinance near-term maturities and reduce revolving credit facility borrowings, underpinning liquidity with a current ratio near 2. These moves collectively aim to restore margin growth amid ongoing net losses and industry pricing pressures.